Table 1 Patient characteristics and treatment data
Characteristics | No. of patients: | Median | Range |
|---|---|---|---|
n = 86 (%) | |||
Age at GK, years | 56 | (24–90) | |
Gender | |||
Male | 52 (60.5) | ||
Female | 34 (39.5) | ||
Extracranial Metastases | |||
Active | 64 (74.4) | ||
Stable | 13 (15.1) | ||
None | 9 (10.5) | ||
Chemotherapy at SRS | |||
Yes | 50 (58.1) | ||
Temozolmide | 13 (15.1) | ||
Ipilimumab | 11 (12.8) | ||
BRAF-inhibitor | 9 (10.5) | ||
None | 36 (41.9) | ||
No. of lesions | |||
1 | 27 (31.4) | ||
2 | 25 (29.1) | ||
3 | 9 (10.5) | ||
4 | 5 (5.8) | ||
5 | 7 (8.1) | ||
6 | 4 (4.7) | ||
≥7 | 9 (10.5) | ||
KPS | |||
<80 | 7 (8.1) | ||
≥80 | 79 (91.8) | ||
RPA Class | |||
I | 6 (6.9) | ||
II | 77 (89.5) | ||
III | 3 (3.5) | ||
Melanoma-GPA points | |||
3.5-4.0 | 22 (25.6) | ||
2.5-3.0 | 35 (40.7) | ||
1.5-2.0 | 26 (30.2) | ||
0-1.0 | 3 (3.5) | ||
Mutation Status | |||
BRAF WT | 31 (36.0) | ||
BRAF V600E, K601E, V600K | 37 (43.0) | ||
c-kit | 2 (2.3) | ||
NRAS | 1 (1.2) | ||
N/A | 15 (17.4) | ||
Total tumor volume, cc | 1.5 | 0.01–34.4 | |
<3 cc | 61 (70.9) | ||
≥3 cc | 25 (29.1) | ||
Marginal GK dose, Gy | 21 | 12–22 | |
Total treatment volume, cc | 3.6 | 0.1–45.2 | |
<7 | 65 (75.6) | ||
≥7 | 21 (24.4) | ||